pharmaphorum

MARCH 23, 2022

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its franchise with a new subcutaneous version of the drug. The post With rivals threatening, Argenx scores key myasthenia gravis win appeared first on.

Antibody 52

Antibody Sales FDA Approval Trials 52

pharmaphorum

DECEMBER 12, 2022

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting. Sales of Argenx’ drug reached $131 million in the third quarter of 2022, and $227 million in the first nine months of the year.

Sales 52

Sales Trials Drugs Antibody 52

XTalks

DECEMBER 21, 2022

Despite the two blockbuster gene therapy approvals, the company sold one of its two priority review vouchers to Argenx SE for $102 million in November to raise some much-needed funds. The company is a leader in the gene therapy space and had been facing significant financial challenges for the past several years.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

Drug Discovery World

NOVEMBER 9, 2023

Vice President, Global Head of Technical Operations, Argenx, on: ‘Studying structure and function of antibodies using innovative chromatographic and mass spectrometric methodologies’. Filip Borgions, Ph.D,

Engineer 52

Engineer Antibody Protein In-Vivo 52